TEL AVIV, Israel, April 24, 2025 /PRNewswire/ — SOLO Wellbeing Ltd. (Headquarter: Israel, CEO: Roy Tal, hereafter “SOLO”) is pleased to announce that its facial analysis AI has been integrated into a personalized aroma recommendation experience, developed in collaboration with NTT East, at the upcoming “Wellness Lounge”, which will have its grand opening on May 19, 2025, in Shinjuku-Hatsudai, Tokyo. This solution has been realized in partnership with NTT Innovation Laboratory Israel Ltd.
The Wellness Lounge is a co-creation-based experimental facility that visualizes users’ mental and physical conditions using advanced technologies and provides personalized experiences and environments accordingly. Operated by NTT East, NTT Data, and Storyline, the project aims to enhance overall life performance through collaboration with various partner companies.
In the “HINATA Area” of the facility, themed around “Awakening,” a space has been designed to promote focus and reduce stress. As part of this, SOLO’s contactless facial analysis AI is utilized to visualize users’ emotional and psychological states.
More specifically, SOLO’s AI is integrated into the personalized aroma recommendation experience co-developed with NTT East. Based on the emotional insights obtained from facial analysis, the system recommends and delivers the optimal aroma for each user, resulting in a more personalized and valuable experience.
About SOLO Wellbeing Ltd.
SOLO is an Israeli company that develops and provides AI-based facial analysis solutions. Through advanced camera-based facial analytics, SOLO’s technology detects and interprets human facial expressions and emotions. This data is integrated into client companies’ products and platforms, contributing to global business growth and operational efficiency.
Website: https://www.imsolo.ai/
Contact for this release:
SOLO Wellbeing Ltd.
Roy Tal
Co-Founder & CEO
Email: roy@imsolo.ai
Photo: https://healthtechnologynet.com/wp-content/uploads/2025/04/SOLO_Wellbeing_LTD.jpg
SOURCE SOLO Wellbeing LTD.
SEATTLE, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage…
– Data support initiation of a combination cohort in the ongoing Phase 1 clinical trial…
SPRING, Texas, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Io Therapeutics, Inc., a privately held pharmaceutical…
Ficerafusp alfa 750mg QW in combination with pembrolizumab demonstrates consistent overall response rate and safety…
TUS+VEN+AZA triplet frontline therapy demonstrates high rates of efficacy and MRD-negative remissions in newly diagnosed…
Demonstrated meaningful overall anemia responses across all patient subgroups, regardless of baseline transfusion status Anemia response…